Search results
Showing 1 to 15 of 29 results for ranibizumab
degeneration (age-related) - ranibizumab and pegaptanib 30 June 2008 TA237 Macular oedema (diabetic) - ranibizumab: appeal...
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
NICE recommends faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.
Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)
NICE is unable to make a recommendation on ranibizumab (Lucentis) for treating diabetic retinopathy because Novartis did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA637
inconvenience, risk of adverse events and – especially when aflibercept or ranibizumab is used – substantial costs. People typically...
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)
NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
Aflibercept for treating choroidal neovascularisation (TA486)
Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.
Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.
further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular...